Patients with Type 1 diabetes and poor glycaemic control frequently display unfavourable lipid profiles and blood pressure, increasing the risk of premature atherosclerosis development and cardiovascular disease (1) . Conversely, patients possessing optimal glycaemic control display lipid profiles comparable to those without diabetes (2) . Continuous subcutaneous insulin infusion (CSII) has been shown to improve glycaemic control and potentially allow the relaxation of diet; however there have been few studies investigating the long-term plasma lipid profiles and blood pressure of patients using the therapy (3) . Medical records containing routine plasma HbA 1c , lipid, lipoprotein and blood pressure measurements from patients undergoing CSII therapy at the Royal Liverpool and Broadgreen University Hospital were utilised. Lipid and lipoprotein data contained in these records spanning an 8 year period (4 years prior to CSII and 4 years after) were analysed within SPSS software using descriptive statistics. HbA 1c and blood pressure information was collected using the same methods; however data for these risk markers were only available for the 4 years after commencement of CSII therapy.
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The study population consisted of 261 patients (33·7% male, 66·3% female); mean age 45±14 years. Fig. 1 shows mean reductions in HbA 1c from 8·3 to 7·9% upon commencement of CSII and mean reductions in systolic and diastolic blood pressure from 128 to 122 mmHg and 75 to 72 mmHg respectively. Furthermore, mean plasma triglycerides increased from 1·0 to 1·3 mmol/l prior to CSII and then decreased to 1·0 mmol/l after the commencement of CSII. An increase was seen in total cholesterol from 4·0 to 4·3 mmol/l prior to CSII; however reductions to 4·0 mmol/l were seen thereafter. LDL increased from 1·9 to 2·1 mmol/l prior to CSII and consequently stabilised at 2·1 mmol/l. HDL remained at 1·7 mmol/l both before and after starting CSII. These findings are in agreement with existing literature which suggests CSII often improves glycaemic control. The results also indicate favourable improvements in lipid profile and blood pressure upon commencement of CSII, which may in turn lead to a reduction in cardiovascular disease risk.
